Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Authors Andrew J Armstrong, Daniel J George

Published 15 November 2007 Volume 2007:3(5) Pages 877—883

Andrew J Armstrong1,2, Daniel J George2

Duke Comprehensive Cancer Center, Departments of 1,2Medicine and 2Surgery, Division of Medical Oncology, Durham, NC, USA

Abstract: Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administration, 2) potential lack of cross-resistance with other platinum agents, 3) clinical benefits seen in early studies of HRPC, and 4) an unmet need in this patient population after docetaxel failure. As men who have progressed after docetaxel and prednisone have an expected median survival of approximately 12 months, there is great opportunity for improved palliation in this disease. Satraplatin may provide a palliative benefit for these men in terms of progression-free survival according to the most recent analyses of the phase III SPARC trial comparing satraplatin and prednisone to prednisone alone in the second-line setting for HRPC, and is currently under USFDA review for this indication. Whether satraplatin and prednisone offer an advantage over docetaxel retreatment or other cytotoxic agents in this setting is an unanswered question and worthy of study. Investigation of predictors of platinum sensitivity and the use of satraplatin in patients with neuroendocrine subsets of metastatic prostate cancer may be warranted given the advances in biomarker and genomic technology and the known sensitivity of small cell cancers to platinum agents. Further study of satraplatin alone or in combination with docetaxel or other molecular and chemotherapeutic agents seems warranted to improve on current outcomes.

Keywords: hormone-refractory prostate cancer, satraplatin, metastatic prostate cancer, SPARC trial, progression-free survival

Download Article [PDF] 

Readers of this article also read:

Paclitaxel attenuates renal interstitial fibroblast activation and interstitial fibrosis by inhibiting STAT3 signaling

Zhang L, Xu X, Yang R, Chen J, Wang S, Yang JQ, Xiang X, He Z, Zhao Y, Dong Z, Zhang D

Drug Design, Development and Therapy 2015, 9:2139-2148

Published Date: 15 April 2015

Formulation of nanotized curcumin and demonstration of its antimalarial efficacy

Ghosh A, Banerjee T, Bhandary S, Surolia A

International Journal of Nanomedicine 2014, 9:5373-5387

Published Date: 20 November 2014

Circulating levels of monocyte chemoattractant protein-1 and interleukin-7 in women who have undergone bilateral salpingo-oophorectomy

Tani A, Yasui T, Matsui S, Kato T, Tsuchiya N, Yuzurihara M, Kase Y, Irahara M

Journal of Inflammation Research 2014, 7:1-7

Published Date: 27 December 2013

Comparative research on the efficacy of CyberKnife® and surgical excision for Stage I hepatocellular carcinoma

Yuan Z, Tian L, Wang P, Song Y, Dong Y, Zhuang H

OncoTargets and Therapy 2013, 6:1527-1532

Published Date: 29 October 2013

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer

Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara Jr PN, de Vere White R, Lam KS, Pan CX

International Journal of Nanomedicine 2012, 7:2793-2804

Published Date: 6 June 2012

Supramolecular micellar nanoaggregates based on a novel chitosan/vitamin E succinate copolymer for paclitaxel selective delivery

Lian H, Sun J, Yu YP, Liu YH, Cao W, Wang YJ, Sun YH, Wang SL, He ZG

International Journal of Nanomedicine 2011, 6:3323-3334

Published Date: 12 December 2011

Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study

Anja Vogt, Ursula Kassner, Ulrike Hostalek, Elisabeth Steinhagen-Thiessen

Vascular Health and Risk Management 2007, 3:467-479

Published Date: 15 September 2007